

M3, Inc.

Presentation Material

October 2019



The following presentation contains forecasts, future plans, management targets and other forward-looking projections relating to M3, Inc. and/or its group. These statements are drawn from assumptions of future events based on data currently available to us, and there exist possibilities that such assumptions are objectively incorrect and/or may produce differing actual results from those mentioned in the statements.

Furthermore, information and data other than those concerning the Company and its subsidiaries/affiliates are quoted from public information, and the Company has not verified and will not warrant its accuracy or dependency.

M3, Inc.

FY2019 H1 Consolidated Results

IFRS


(mn yen)	FY2018 H1	FY2019 H1	YoY
Sales	53,275	61,545	+16%
Operating Profit	13,875	16,549	+19%
Pre-tax Profit	13,993	16,597	+19%
Net Profit	9,626	11,312	+18%

FY2019 H1 Consolidated Results by Segment

(mn yen)			FY2018 H1	FY2019 H1	YoY
Domestic	Medical Platform	Sales	18,403	22,269	+21%
		Profit	6,134	7,404	+21%
	Evidence Solution	Sales	10,975	10,739	-2%
		Profit	2,764	2,209	-20%
	Career Solution	Sales	7,711	8,760	+14%
		Profit	2,750	3,150	+15%
	Other Emerging Businesses	Sales	5,640	7,140	+27%
		Profit	665	902	+36%
Overseas		Sales	11,778	13,977	+19%
		Profit	1,553	2,667	+72%

Consolidated Operating Profit Change Analysis

Unit: mn yen



FY2019 H1 Overview

Medical Platform

- Aggressive upfront investments beginning to contribute. Marketing service orders grew 41% yoy in H1, with newly consolidated Ultmarc also contributing
- Upfront investment in Y's impacted profits negatively by 220 mn yen; profit growth would otherwise have been 24% yoy

Evidence Solution

- Temporary dip due to ending of large scale PV projects
- Orders backlog steady at 24 bn yen

Career Solution

- Both physician and pharmacist inflow remains robust, with sales at 8.8 bn yen (+14% yoy) and operating profit at 3.1 bn yen (+15% yoy)

Emerging Businesses


- Multiple new businesses in growth phase, with favorable progress of incubation investments (StemRim IPO)

Overseas

- Healthy US business growth and rapid APAC expansion brought sales to 1.4 bn yen (+19% yoy) and o.p. to 2.7 bn yen (+72%)
- APAC business now on growth trajectory, expected to maintain course


7P

- Established Stream-I, Inc., a JV with Shionogi & Co., Ltd. with aim to create therapeutic solutions with areas starting with influenza




Doctor's Time Allocation vs Pharma's Budget Allocation

Doctors spend the most time collecting information via the Internet. However, pharmaceutical firms operating in Japan spend the majority of their marketing budget on off-line sales rep related costs.



Medical Platform Growth Potential in Japan




In addition to pharma companies, sales from device companies are growing


Sales from **Device Companies** grew over **2x** YoY

Recovery in Marketing Support Service Orders

Marketing Support Service Orders




- New staff development and orders both accelerating in tandem
- Double digit sales growth expected in FY19 with expansion in both personnel and project scale



Sales and Profit Trend of Evidence Solution

(mn yen)




- Ongoing projects continue steadily, while completion of large projects created a momentary dip
- Backlog remains steady at 24 bn yen. Upfront personnel investment in line with orders growth
- Acquired companies causing transitory pull down effect on margins
- Integration of 3 SMOs planned to maximize synergies

M3 Group: Accelerated Trial Completion


- Mr. Finder finds highly motivated doctors at sites with potential patients
- Trial process management executed in similar fashion to web based marketing (High speed PDCA, conversion management, IT tools utilization)

Global Trial: Endocrinology/ Metabolism




**Completed patient enrollment in
20 months vs. allocated 33 months**

Domestic Trial: Endocrinology/Metabolism




**Completed patient enrollment in
10 months vs. allocated 15 months**



Sales and Profit Trend of Career Solutions


(mn yen)

■ Sales
■ Segment Profit




FY19 FCT
16 bn yen

- Business scope expansion from increase in staff and productivity
- Fully absorbed hiring impact, resulting in accelerated growth rate
- Upfront investment expected to continue in FY19, and may slightly dampen margins




Sales and Profit Trend of Emerging Businesses

(mn yen)




- Each business on steady growth path, with expansion in next growth drivers
- Seeds rocket investment StemRim IPO gained high valuation
- Overall profits grew +36% despite deconsolidation of Honyaku Center reduced affiliate income by 70 mn yen



Number of Physician Members and Panelists (Global)


(thousand)



👉 Close to 50% coverage of the total 12 million global doctors

Sales and Profit Trend of Overseas

(mn yen)




FY19 FCT
30 bn yen

- 80% of profit growth was from Asia, 20% was from U.S. clinical trials and career business
- Business expansion acceleration in all APAC countries (China, India, and Korea)
- China: Sales +50% yoy, profit grew 4x
Korea: Sales +30% yoy, profit +70%

China: Membership Expansion

Number of Physician Members in China

(thousands)



- Marketing services for drug companies starting with MR-kun, and research services showed steady growth
- MR-kun is now being utilized by 15 pharma companies across 37 drugs
- Newly approaching local clients, in addition to MNCs
- Launched career services for physicians



Topped 2.87 million physicians members, covering over 2/3 of doctors in China

New Initiatives Update

Business Scope Expansion and Growth Potential

	2010	2014	2018	2022
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	→
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	→
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	→
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	→

Similar pace of growth expected over the next 4 years

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Business Scope Expansion and Growth Potential

	2010	2014	2018	Recent Strategic Development
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	<ul style="list-style-type: none"> Stream-I CaNoW 1P1Y Fund
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	<ul style="list-style-type: none"> Entry into EHR business in France
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Business Scope Expansion and Growth Potential

	2010	2014	2018	Recent Strategic Development
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	<div> <div>Stream-I</div> <div>CaNoW</div> <div>1P1Y Fund</div> </div>
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	<div> <div>Entry into EHR business in France</div> </div>
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	


 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Comparing Healthcare to Typical Businesses

Typical Business

Product
Provider

Client




Simple “Make & Sell” world

Healthcare Business


Product
Provider

Client



A world where “Win-win” solutions are required to satisfy multiple “clients”


4Ps of Marketing is not enough










 There is a limit to the 4P theory when dealing with Medical issues...

7Ps of Healthcare Business


3: 7P



7P: a Problem Solving Framework for Healthcare

7 P's	Description	Example
 <ul style="list-style-type: none"> ■ Performance Target 	<ul style="list-style-type: none"> ■ Concrete directionality of solution 	<ul style="list-style-type: none"> ■ Patient reduction ■ Medical cost redux
 <ul style="list-style-type: none"> ■ Philosophy 	<ul style="list-style-type: none"> ■ Fundamental principle 	<ul style="list-style-type: none"> ■ Overall optimum over local optimum
 <ul style="list-style-type: none"> ■ Technology Platform 	<ul style="list-style-type: none"> ■ Products/ technology and their utilization 	<ul style="list-style-type: none"> ■ Diagnostic and treatment technology ■ A.I., Genome
 <ul style="list-style-type: none"> ■ Place / Process 	<ul style="list-style-type: none"> ■ Place of medical care delivery 	<ul style="list-style-type: none"> ■ Hospital ■ Home care, hospital coordination
 <ul style="list-style-type: none"> ■ Payment System 	<ul style="list-style-type: none"> ■ Payment system, cash flow 	<ul style="list-style-type: none"> ■ Medical and long-term care insurance, patient expenses
 <ul style="list-style-type: none"> ■ People / Player 	<ul style="list-style-type: none"> ■ Healthcare service provider 	<ul style="list-style-type: none"> ■ Doctors, medical sites ■ Cloud workers
 <ul style="list-style-type: none"> ■ Public Policy 	<ul style="list-style-type: none"> ■ Legal and political frameworks 	<ul style="list-style-type: none"> ■ Insurance system, medical regulations

Establishment of Stream-I, Inc. with Shionogi & Co., Ltd.



Strategic Significance of the JV




October 4th Press Conference
Left: Ms. Sawada, Executive Vice President of Shionogi & Co, Inc. (CEO of Stream-I)

- **Provide holistic disease solutions through not only pharmaceuticals, but via merging of technology and peripheral services (such as AI, LINE healthcare, drug delivery, etc.)...
A true “7P” project**
- **A large step in commitment towards creating solutions to medical issues by
conjoining forces (JV) with a
pharmaceutical company**
- **M3 aims to join forces with other companies in addressing challenges surrounding various diseases...
STREAM-I is a significant precedent**

Expansion of M3's Addressable Market


Former Market

National Healthcare Expenditure (Japan)
42.4 trillion yen



7P Project Market

National Healthcare Expenditure (Japan)
42.4 trillion yen



Creating solutions across the entire healthcare eco-system (7P Project), not limited to marketing and R&D, expands our addressable market from 4 trillion yen to 40 trillion yen, and up to 500 trillion yen including overseas markets.

Business Scope Expansion and Growth Potential

	2010	2014	2018	Recent Strategic Development
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	<ul style="list-style-type: none"> Stream-I CaNoW 1P1Y Fund
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	<ul style="list-style-type: none"> Entry into EHR business in France
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

CaNoW is...

A project to grant the wishes of patients through corporate sponsorship

CaNoW

Can + Now

“I wish to visit my workplace where I haven’t been to since I became ill.”

“I wish to attend the wedding of my grandchild, who lives far away.”

“I wish to visit the diner where I frequented when I was a student.”

Especially when the end seems near, CaNoW strives to re-spark the passion for life.

CaNoW Concept

“Find the **passion** to live
by bringing **dreams** to **reality**”

Common Issues



Patient

- Solely focused on treatment from illness
- Feel “defeated” without recovery or improvement



Physician

- Difficult to provide support outside of treatment
- Little options in later stages of illness

**CaNoW
actualizes
patient
“dreams”
into reality**

Aspired Direction

- Focus on the “passion” to live
- A life with joy is a life of “victory”
- Support to make the “passion” into reality without burdens on the physician
- Full patient support

CaNoW Solutions

Problem

1. Full support of medically certified staff



- Where can I find appropriate supporters



CaNoW Support

- Support from 460,000 qualified medical staff, over 200 support staff across Japan, and M3 group's 900 medical certificate holders
- Arrangement according to required medical care and execution (cost consciousness)

2. Planning and execution ability



- What do I really want to do
- How do I bring it to reality



- Careful consultation to identify true "wishes"
- Materialize wishes through collaboration with travel agencies and corporate alliances, IT services

3. Coordination with medical facilities



- Primary physician advises against it
- Care providers and sites do not permit excursions



- Certified staff will confirm patient condition and level of required medical care to convince primary care providers

CaNoW

Produced by  M3, Inc.

**CaNoW aims to fulfill over 1000 patient wishes
over the next 3 years**

**Creating a social movement to
“overcome illness, and illuminate lives”**

Business Scope Expansion and Growth Potential

	2010	2014	2018	Recent Strategic Development
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	<ul style="list-style-type: none"> Stream-I CaNoW 1P1Y Fund
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	<ul style="list-style-type: none"> Entry into EHR business in France
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Establishment of Internal CVC* “1P1Y Fund”

M3's Mission:

“Making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs”

Investment Line

10 billion yen

Investment Size

Average few hundred million yen per investment to a maximum of approximately 2 billion yen

Investment Region

Domestic and Global

Investment Target


Venture companies, listed companies, pharmaceutical and medical device pipelines, others.

Investment Themes

AI, medical devices (including software), advanced medical technologies, rare diseases, healthcare management

* CVC: Corporate Venture Capital, an initiative where an operating company makes investments to create synergies with a venture company

Advantages of the 1P1Y Fund



Realize high returns through maximization of m3.com resources and extensive investment track record

Business Scope Expansion and Growth Potential

	2010	2014	2018	Recent Strategic Development
Country	: 3	→ 5 (1.5x)	→ 10 (3x)	<ul style="list-style-type: none"> Stream I CaNoW 1P1Y Fund
Business Types	: 6	→ 10 (1.5x)	→ 26 (4x)	
Business Units (Type x Country)	: 10	→ 18 (2x)	→ 41 (4x)	<ul style="list-style-type: none"> Entry into EHR business in France
Sales (bn)	: 140	→ 370 (2.5x)	→ 945 (7x)	

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**


Overview of Weda S.A.S.



- Headquarters: Montpellier (France)
- Established: 2010

- Description of Business: Development and sales of cloud based electronic health records (EHR)
 - **Over 50% EHR market share in France's**
 - Over 90% of GPs use EHRs in France
 - Continued migration to cloud based EHRs
 - **Over 25 million patient data**
 - Approximately 10,000 users (of which 60% are doctors)

- CEO: Fabrice Greenbaum (30+ years of experience across 3 EHR companies as founder/CEO)
- Employees: approx. 40



- **Business Expansion in France: entry into cloud based EHR business**
 - **First entry into new business outside of anglo-phone countries**
 - **Low risk entry by vertical integration of long-standing customer base**
- **Expansion through complementary businesses synergies of both Vidal and Weda**
 - **Increase in user base for both companies**
- **Future aim to develop new services utilizing the strengths of both companies**

Business Scope Expansion and Growth Potential


	2010	2014	2018	2022
Country	: 3 →	5 (1.5x) →	10 (3x) →	
Business Types	: 6 →	10 (1.5x) →	26 (4x) →	Similar pace of growth expected over the next 4 years
Business Units (Type x Country)	: 10 →	18 (2x) →	41 (4x) →	
Sales (bn)	: 140 →	370 (2.5x) →	945 (7x) →	

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Annual Results & Forecast for FY2019


Sales

(mn yen)



Operating Profit & Net Profit

(mn yen)



* FY17 results retroactively restated according to IFRS9 (Financial Instruments)

Creating New Value in Healthcare

M3

Medicine

Media

Metamorphosis



Healthcare sector is enormous...

“Making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs”

- this is both the desire and goal of M3.

Aim to create new value

- **Provide solutions within the healthcare sector**
- **Provide new and unique business models**
- **Specialize in niches areas that provide opportunity for high value creation and high profits in order to boost enterprise value**